This company listing is no longer active
0A5R Stock Overview
A commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Calliditas Therapeutics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 207.00 |
| 52 Week High | SEK 208.20 |
| 52 Week Low | SEK 81.50 |
| Beta | 1.46 |
| 11 Month Change | -0.29% |
| 3 Month Change | 0.58% |
| 1 Year Change | 114.51% |
| 33 Year Change | 113.44% |
| 5 Year Change | n/a |
| Change since IPO | 33.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A5R | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0.1% | 4.2% | 1.7% |
| 1Y | 114.5% | 3.0% | 8.4% |
Return vs Industry: 0A5R exceeded the UK Pharmaceuticals industry which returned 3.8% over the past year.
Return vs Market: 0A5R exceeded the UK Market which returned 6.6% over the past year.
Price Volatility
| 0A5R volatility | |
|---|---|
| 0A5R Average Weekly Movement | 0.6% |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0A5R has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0A5R's weekly volatility has decreased from 13% to 1% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 222 | Renee Aguiar-Lucander | www.calliditas.se |
Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company’s lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome.
Calliditas Therapeutics AB (publ) Fundamentals Summary
| 0A5R fundamental statistics | |
|---|---|
| Market cap | SEK 11.24b |
| Earnings (TTM) | -SEK 480.36m |
| Revenue (TTM) | SEK 1.60b |
7.0x
P/S Ratio-23.4x
P/E RatioIs 0A5R overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A5R income statement (TTM) | |
|---|---|
| Revenue | SEK 1.60b |
| Cost of Revenue | SEK 104.68m |
| Gross Profit | SEK 1.50b |
| Other Expenses | SEK 1.98b |
| Earnings | -SEK 480.36m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 11, 2024
| Earnings per share (EPS) | -8.89 |
| Gross Margin | 93.46% |
| Net Profit Margin | -30.00% |
| Debt/Equity Ratio | 920.0% |
How did 0A5R perform over the long term?
See historical performance and comparison